BioNxt Solutions在八个国家获得了一种次级语言的抗癌药物交付方法的重要专利权,支持其多种硬化药物BNT23001。 BioNxt Solutions got a key patent in eight countries for a sublingual anticancer drug delivery method, supporting its multiple sclerosis drug, BNT23001.

BioNxt Solutions Inc. 收到了欧亚专利组织发出的“对赠款的准备”通知,申请一项专利,涉及以次语种提供抗癌药物治疗自发免疫和神经退化疾病的专利,涵盖人口超过2亿的八个国家。 BioNxt Solutions Inc. received a "Readiness to Grant" notice from the Eurasian Patent Organization for a patent covering sublingual delivery of anticancer drugs to treat autoimmune and neurodegenerative diseases, spanning eight countries with over 200 million people. 专利, 待最后的费用支付, 支持公司的首要药物, BNT23001, 语言下克拉迪宾配方治疗多发性硬化症. The patent, pending final fee payment, supports the company’s lead drug, BNT23001, a sublingual Cladribine formulation for multiple sclerosis. BioNxt公司正在准备在人类试验之前进行大规模动物生物等效研究,并在欧盟、加拿大、澳大利亚、新西兰、日本和美国寻求全球专利保护。 BioNxt is preparing a large-scale animal bioequivalence study ahead of human trials and is pursuing global patent protection in the EU, Canada, Australia, New Zealand, Japan, and the U.S. 欧洲和欧亚专利局都证实了该技术的新颖性和工业适用性。 Both the European and Eurasian patent offices confirmed the technology’s novelty and industrial applicability. 该公司开发先进的药物运载系统,在北美和欧洲经营研发设施,并侧重于欧洲监管批准。 The company, which develops advanced drug delivery systems, operates R&D facilities in North America and Europe and is focused on European regulatory approvals. 它列在加拿大证券交易所、OTCQB和法兰克福证券交易所上。 It is listed on the Canadian Securities Exchange, OTCQB, and Frankfurt Stock Exchange.